药物涂层球囊在冠状动脉原位病变中的应用现状

杨新越; 潘亮; 郑悠阳; 邱春光

doi:10.13201/j.issn.1001-1439.2021.08.003

药物涂层球囊在冠状动脉原位病变中的应用现状

- 郑州大学第一附属医院心内科(郑州, 450052)

详细信息

通讯作者: 邱春光,E-mail:qiuchunguang0123@163.com

中图分类号: R543.3

收稿日期: 2021-01-14

Application of drug-coated balloons in de novo coronary lesions

- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

More Information

Corresponding author: QIU Chunguang, E-mail: qiuchunguang0123@163.com

Received Date: 14 January 2021

摘要

摘要: 药物涂层球囊的出现使得冠状动脉介入治疗进入新阶段,其在支架内再狭窄中已经取得了成功的应用。近年来,越来越多的证据表明其可用于小血管病变中。然而,药物涂层球囊在其他原位病变如分叉、弥漫性、慢性完全闭塞等病变中的应用仍存在局限。但随着“介入无植入”理念的深入,药物涂层球囊由于自身的特性将会呈现出更多的优势。本文就药物涂层球囊在冠状动脉原位病变中的应用作一综述。
- 药物涂层球囊 /
- 冠状动脉原位病变 /
- 小血管病变 /
- 分叉病变 /
- 急性心肌梗死
Abstract: Drug-coated balloon(DCB) has emerged as a promising therapy particularly in the treatment of in-stent restenosis. In recent years, accumulating evidence has proved that it can be used in small vessel diseases. However, the application of DCB in other de novo coronary lesions such as bifurcation, diffuse, chronic total occlusion, and other lesions still has limitations. But with the deepening of the concept of "Nothing Left", DCB will show more advantages due to its characteristics. This article reviews the research progress of the application of DCB in de novo coronary artery lesions.
- drug-coated balloon /
- de novo coronary artery lesion /
- small vessel lesion /
- bifurcation lesion /
- acute myocardial infarction

HTML全文

参考文献(43)

[1]	Morice MC,Serruys PW,Sousa EJ,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J].New Engl J Med,2002,346(23):1773-1780.
[2]	Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.
[3]	McFadden EP,Stabile E,Regar E,et al.Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy[J].Lancet,2004,364(9444):1519-1521.
[4]	Nordmann AJ,Briel M,Bucher HC.Mortality in randomized controlled trials comparing drug-eluting vs.bare metal stents in coronary artery disease:a meta-analysis[J].Eur Heart J,2006,27(23):2784-2814.
[5]	Stone GW,Ellis SG,Cox DA,et al.A polymer-based,paclitaxel-eluting stent in patients with coronary artery disease[J].New Engl J Med,2004,350(3):221-231.
[6]	Lasala JM,Stone GW,Dawkins KD,et al.An overview of the TAXUS Express,paclitaxel-eluting stent clinical trial program[J].J Interv Cardiol,2006,19(5):422-431.
[7]	Ang H,Lin J,Huang YY,et al.Drug-coated balloons:technologies and clinical applications[J].Curr Pharm Des,2018,24(4):381-396.
[8]	Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J].N Engl J Med,2006,355(20):2113-2124.
[9]	Byrne RA,Neumann FJ,Mehilli J,et al.Paclitaxel-eluting balloons,paclitaxel-eluting stents,and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3):a randomised,open-label trial[J].Lancet,2013,381(9865):461-467.
[10]	Adriaenssens T,Dens J,Ughi G,et al.Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs.everolimus-eluting stents for in-stent restenosis:the SEDUCE(Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis)randomised clinical trial[J].EuroIntervention,2014,10(4):439-448.
[11]	Alfonso F,Perez-Vizcayno MJ,Cardenas A,et al.A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis:the RIBS V Clinical Trial(Restenosis Intra-stent of Bare Metal Stents:paclitaxel-eluting balloon vs.everolimus-eluting stent)[J].J Am Coll Cardiol,2014,63(14):1378-1386.
[12]	Alfonso F,Pérez-Vizcayno MJ,Cárdenas A,et al.A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents:The RIBS IV Randomized Clinical Trial[J].J Am Coll Cardiol,2015,66(1):23-33.
[13]	Baan J Jr,Claessen BE,Dijk KB,et al.A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis:The DARE Trial[J].JACC Cardiovasc Interv,2018,11(3):275-283.
[14]	Mennuni MG,Pagnotta PA,Stefanini GG.Coronary stents:the impact of technological advances on clinical outcomes[J].Ann Biomed Eng,2016,44(2):488-496.
[15]	Axel DI,Kunert W,Goggelmann C,et al.Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery[J].Circulation,1997,96(2):636-645.
[16]	Abal M,Andreu JM,Barasoain I.Taxanes:microtubule and centrosome targets,and cell cycle dependent mechanisms of action[J].Curr Cancer Drug Targets,2003,3(3):193-203.
[17]	Granada JF,Stenoien M,Buszman PP,et al.Mechanisms of tissue uptake and retention of paclitaxel-coated balloons:impact on neointimal proliferation and healing[J].Open Heart,2014,1(1):e000117.
[18]	Speck U,Stolzenburg N,Peters D,et al.How does a drug-coated balloon work?Overview about coating technologies and their impact[J].J Cardiovasc Surg(Torino),2015.
[19]	Iqbal J,Gunn J,Serruys PW.Coronary stents:historical development,current status and future directions[J].Br Med Bull,2013,106:193-211.
[20]	Alfonso F,García-Guimaraes M.Optimal coronary interventions in small vessels:Is size all that matters?[J].JACC Cardiovasc Interv,2016,9(13):1335-1337.
[21]	Meneguz-Moreno RA,Ribamar Costa J Jr,Abizaid A.Drug-coated balloons:hope or hot air:update on the role of coronary DCB[J].Curr Cardiol Rep,2018,20(10):100.
[22]	Unverdorben M,Kleber FX,Heuer H,et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study:are lesions clinically stable from 12 to 36 months?[J].EuroIntervention,2013,9(5):620-628.
[23]	Unverdorben M,Kleber FX,Heuer H,et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study:are lesions clinically stable from 12 to 36 months?[J].EuroIntervention,2013,9(5):620-628.
[24]	Latib A,Ruparelia N,Menozzi A,et al.3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study(BELLO)[J].JACC Cardiovasc Interv,2015,8(8):1132-1134.
[25]	Jeger RV,Farah A,Ohlow MA,et al.Drug-coated balloons for small coronary artery disease(BASKET-SMALL 2):an open-label randomised non-inferiority trial[J].Lancet,2018,392(10150):849-856.
[26]	Hildick-Smith D,Behan MW,Lassen JF,et al.The EBC TWO Study(European Bifurcation Coronary TWO):A Randomized Comparison of Provisional T-Stenting Versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations[J].Circ Cardiovasc Interv,2016,9(9).
[27]	Berland J,Lefèvre T,Brenot P,et al.DANUBIO-a new drug-eluting balloon for the treatment of side branches in bifurcation lesions:six-month angiographic follow-up results of the DEBSIDE trial[J].EuroIntervention,2015,11(8):868-876.
[28]	Jim MH,Lee MK,Fung RC,et al.Six month angiographic result of supplementary paclitaxel-eluting balloon deployment to treat side branch ostium narrowing(SARPEDON)[J].Int J Cardiol,2015,187:594-597.
[29]	Worthley S,Hendriks R,Worthley M,et al.Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations:12-month results of the multicenter BIOLUX-I study[J].Cardiovasc Revasc Med,2015,16(7):413-417.
[30]	Lozano I,Capin E,de la Hera JM,et al.Diffuse coronary artery disease not amenable to revascularization:long-term prognosis[J].Rev Esp Cardiol(Engl Ed),2015,68(7):631-633.
[31]	Jurado-Román A,Abellán-Huerta J,Requena JA,et al.Comparison of clinical outcomes between very long stents and overlapping stents for the treatment of diffuse coronary disease in real clinical practice[J].Cardiovasc Revasc Med,2019,20(8):681-686.
[32]	Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J].EuroIntervention,2019,40(2):87-165.
[33]	Basavarajaiah S,Latib A,Shannon J,et al.Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease:real-world experience from our registry[J].J Interv Cardiol,2014,27(4):348-355.
[34]	Vos NS,Dirksen MT,Vink MA,et al.Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam(PAPPA):one-year clinical outcome of a pilot study[J].EuroIntervention,2014,10(5):584-590.
[35]	Belkacemi A,Agostoni P,Nathoe HM,et al.First results of the DEB-AMI(drug eluting balloon in acute ST-segment elevation myocardial infarction)trial:a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic,intravascular,functional,and clinical outcomes[J].J Am Coll Cardiol,2012,59(25):2327-2337.
[36]	Nijhoff F,Agostoni P,Belkacemi A,et al.Primary percutaneous coronary intervention by drug-eluting balloon angioplasty:the nonrandomized fourth arm of the DEB-AMI(drug-eluting balloon in ST-segment elevation myocardial infarction)trial[J].Catheter Cardiovasc Interv,2015,86 Suppl 1:S34-44.
[37]	Vos NS,Fagel ND,Amoroso G,et al.Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction:The REVELATION Randomized Trial[J].JACC Cardiovasc Interv,2019,12(17):1691-1699.
[38]	Yu X,Ji F,Xu F,et al.Treatment of large de novo coronary lesions with paclitaxel-coated balloon only:results from a Chinese institute[J].Clin Res Cardiol,2019,108(3):234-243.
[39]	Lu W,Zhu Y,Han Z,et al.Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels[J].J Cardiol,2019,73(2):151-155.
[40]	Cortese B,Buccheri D,Piraino D,et al.Drug-coated balloon without stent implantation for chronic total occlusion of coronary arteries:Description of a new strategy with an optical coherence tomography assistance[J].Int J Cardiol,2015,191:75-76.
[41]	Cortese B,Buccheri D,Piraino D,et al.Drug-coated balloon angioplasty:An intriguing alternative for the treatment of coronary chronic total occlusions[J].Int J Cardiol,2015,187:238-239.
[42]	Cortese B,Buccheri D,Piraino D,et al.Drug-coated balloon angioplasty for coronary chronic total occlusions.An OCT analysis for a "new" intriguing strategy[J].Int J Cardiol,2015,189:257-258.
[43]	Koln PJ,Scheller B,Liew HB,et al.Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting-A feasibility and safety study[J].Int J Cardiol,2016,225:262-267.